Madrigal Pharmaceuticals 過去の業績
過去 基準チェック /06
Madrigal Pharmaceuticalsの収益は年間平均-12%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間29.1% 93.9%割合で 増加しています。
主要情報
-11.96%
収益成長率
-4.91%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | 93.87% |
| 株主資本利益率 | -47.83% |
| ネット・マージン | -30.08% |
| 次回の業績アップデート | 06 May 2026 |
最近の業績更新
Recent updates
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Apr 28
MDGL: Gross To Net Execution And Margin Pressure Will Shape Balanced Outlook
Analysts have reset Madrigal Pharmaceuticals' price target to $529 from $570, reflecting updated forecasts that factor in recent commentary on gross to net adjustments, as well as revised assumptions for growth, profitability, and forward P/E. Analyst Commentary Bearish analysts have trimmed expectations for Madrigal Pharmaceuticals, pointing to updated assumptions around gross to net adjustments, as well as revisions to growth, profitability, and P/E assumptions.MDGL: Gross To Net Execution And Cirrhosis Expansion Will Shape Balanced Outlook
Analyst price targets on Madrigal Pharmaceuticals have been reset to $529, with the change largely tied to updated forecasts that factor in comments on gross to net adjustments. Other recent research has introduced new bullish coverage and higher targets from different firms.MDGL: MASH Combinations And Cirrhosis Expansion Will Shape Balanced Future Outlook
Analysts now set a consolidated price target for Madrigal Pharmaceuticals at $529, down from previous levels such as $570, reflecting updated forecasts around gross-to-net adjustments, even as model assumptions for revenue growth, profit margins, and future P/E remain broadly consistent. Analyst Commentary Recent research updates on Madrigal Pharmaceuticals show a mix of support and caution, with several bearish analysts rethinking how much upside is left after the stock's strong prior move and the latest company updates.MDGL: Cirrhosis Expansion And MASH Combinations Will Drive Future Repricing
Analysts now set the fair value estimate for Madrigal Pharmaceuticals at $529, up $27 from $502. This reflects updated models that factor in gross to net adjustments, recent licensing activity, and mixed revisions to Street price targets across firms.
MDGL: MASH Franchise And DGAT2 Combo Plans Will Drive Future Upside
Madrigal Pharmaceuticals' updated analyst price target reflects a modest adjustment, with fair value edging from about $900.66 to $904.36 as analysts factor in recent target cuts around $529 to $570, alongside fresh bullish initiation and higher targets above $600 tied to updated product and combination-therapy assumptions. Analyst Commentary Recent Street research on Madrigal Pharmaceuticals shows a mix of caution and optimism, with valuation debate sitting alongside higher fair value estimates tied to execution on its MASH franchise and new pipeline additions.
MDGL: Future Leadership Will Rely On MASH Cirrhosis Uptake Versus GLP 1 Pressure
The analyst price target for Madrigal Pharmaceuticals has been revised higher to $671.07, up from $603.47. Analysts now factor in updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E, following recent research that highlights both enthusiasm for Rezdiffra's commercial potential and some valuation concerns.MDGL: MASH Franchise Expansion And New DGAT2 Combo Study Will Drive Upside
The updated analyst price target for Madrigal Pharmaceuticals moves from about $567 to roughly $901 per share, with analysts pointing to stronger modeled profitability, a higher assumed future P/E multiple, and continued enthusiasm for Rezdiffra across multiple research updates. Analyst Commentary Recent research coverage on Madrigal Pharmaceuticals has leaned positive overall, with a series of price target increases and a few ratings changes that highlight how divided views are at current levels.MDGL: Cirrhosis Expansion And Combination Plans Will Test High Expectations
Analysts have modestly adjusted their price targets for Madrigal Pharmaceuticals, with a slight upward shift reflected in updated models that factor in Rezdiffra uptake, expanded MASH opportunities including potential combinations with ervogastat, and a range of views on valuation and longer term penetration assumptions. Analyst Commentary Recent research on Madrigal Pharmaceuticals shows a mix of optimism around Rezdiffra and its potential role in MASH, paired with increasingly careful debate around valuation, competitive pressures, and execution risks.MDGL: Elevated Expectations For Cirrhosis Opportunity Will Face Heightened Competitive Pressures
Madrigal Pharmaceuticals' analyst price target has risen sharply from approximately $312 to $502 per share, as analysts factor in stronger long term profitability and higher penetration assumptions for Rezdiffra across F2-F3 and F4c MASH populations, despite moderating top line growth expectations and a modestly higher discount rate. Analyst Commentary Recent Street research reflects a broadly constructive outlook on Madrigal Pharmaceuticals, with multiple firms lifting price targets in response to stronger than expected Rezdiffra uptake and expanding commercial visibility in both F2 F3 and compensated F4c MASH populations.MDGL: Future Leadership Will Depend On Cirrhosis Uptake Amid GLP 1 Competition
The analyst price target for Madrigal Pharmaceuticals has been raised by approximately $40 per share, as analysts cite stronger-than-expected real-world uptake of Rezdiffra, expanded penetration assumptions across F2, F3, and emerging F4c populations, and increased confidence in the drug's long-term commercial trajectory despite GLP-1 competition. Analyst Commentary Recent Street research reflects a strongly constructive tone on Madrigal Pharmaceuticals, with multiple firms lifting price targets into the mid to high $500s and $600s range, underpinned by faster than expected Rezdiffra adoption and expanding addressable populations across F2, F3, and emerging F4c disease.MDGL: Future Leadership Will Depend On Expanding MASH Cirrhosis And Fibrosis Therapy Adoption
Madrigal Pharmaceuticals' analyst price target has been raised into the low to mid $600s per share from the high $500s, as analysts factor in stronger long term profitability expectations and sustained Rezdiffra uptake across F2-F3 and emerging F4c populations. Analyst Commentary Bullish analysts are increasingly constructive on Madrigal's outlook as they update models to reflect stronger real world Rezdiffra uptake, expanded addressable populations and emerging combination therapy optionality.MDGL: Future Leadership Will Depend On Expanding Liver Fibrosis Therapy Penetration Amid Competition
Madrigal Pharmaceuticals’ analyst price target has been raised from approximately $536 to $564 per share. This reflects increased confidence among analysts in Rezdiffra’s market penetration and longer-term growth prospects, despite evolving competitive dynamics.Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 26% Price Boost Is Out Of Tune With Revenues
Nov 12
MDGL: Future Revenue Leadership Will Depend On Therapy Adoption Amid Rising Competition
The analyst consensus price target for Madrigal Pharmaceuticals has increased by approximately $23 to $536, as analysts cite continued strength from Rezdiffra as well as improved long-term profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased price targets for Madrigal Pharmaceuticals, emphasizing Rezdiffra’s ongoing outperformance and supportive market dynamics, even as new competitors enter the F2-F3 MASH segment.EU Expansion and Combination Therapies Will Drive Future Opportunity
Analysts have increased their price target for Madrigal Pharmaceuticals by approximately $100. They now expect shares to reach around $550, citing Rezdiffra's robust launch progress, new approvals, and potential from combination therapy strategies.US Patent And EU Expansion Will Secure Future Potential
The analyst price target for Madrigal Pharmaceuticals has increased by approximately $8 to $489.54. Analysts cite stronger-than-expected revenue growth, improved profit margins, and favorable momentum following recent approvals and positive market dynamics.US Patent And EU Expansion Will Secure Future Potential
Analysts raised Madrigal Pharmaceuticals’ price target to $481.85, citing strong EU approval momentum, first-mover advantage for Rezdiffra in MASH, guideline inclusion, and extended patent protection driving long-term value. Analyst Commentary Bullish analysts cite Madrigal’s strong positioning to dominate the metabolic dysfunction-associated steatohepatitis (MASH) treatment landscape through its proprietary thyroid hormone receptor-beta platform.US Patent And EU Expansion Will Secure Future Potential
Madrigal Pharmaceuticals’ consensus price target has been raised to $466.38 as analysts cite EU conditional approval, first-line therapy status, improved sales visibility, and extended patent protection for Rezdiffra as key drivers strengthening blockbuster potential and reducing risk. Analyst Commentary Bullish analysts believe Madrigal is uniquely positioned to dominate the metabolic dysfunction-associated steatohepatitis (MASH) market, leveraging its thyroid hormone receptor-beta platform.US Patent And EU Expansion Will Secure Future Potential
The consensus analyst price target for Madrigal Pharmaceuticals was raised from $449.57 to $461.43, primarily driven by the EU approval and expanded patent protection for Rezdiffra, which de-risks future cash flows and supports robust sales expectations in a large addressable market. Analyst Commentary Bullish analysts updated their models to reflect the recent EU approval of Rezdiffra, reducing risk and subsequently lowering the discount rate applied to future cash flows.Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues
Aug 22Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Aug 13Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 08Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 04
FDA Approval Will Expand MASH Treatment Market Reach
First FDA-approved MASH treatment and strong U.S. market launch position Madrigal Pharmaceuticals for significant revenue growth.Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Feb 26Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
Jan 19Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Jan 09Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09収支内訳
収支内訳
Madrigal Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 25 | 958 | -288 | 814 | 389 |
| 30 Sep 25 | 741 | -289 | 715 | 298 |
| 30 Jun 25 | 516 | -282 | 614 | 193 |
| 31 Mar 25 | 317 | -392 | 522 | 210 |
| 31 Dec 24 | 180 | -466 | 435 | 237 |
| 30 Sep 24 | 77 | -519 | 340 | 282 |
| 30 Jun 24 | 15 | -510 | 260 | 284 |
| 31 Mar 24 | 0 | -444 | 173 | 281 |
| 31 Dec 23 | 0 | -374 | 108 | 272 |
| 30 Sep 23 | 0 | -347 | 76 | 272 |
| 30 Jun 23 | 0 | -330 | 61 | 270 |
| 31 Mar 23 | 0 | -315 | 55 | 260 |
| 31 Dec 22 | 0 | -295 | 48 | 245 |
| 30 Sep 22 | 0 | -274 | 45 | 228 |
| 30 Jun 22 | 0 | -256 | 41 | 214 |
| 31 Mar 22 | 0 | -247 | 40 | 207 |
| 31 Dec 21 | 0 | -242 | 37 | 205 |
| 30 Sep 21 | 0 | -236 | 32 | 206 |
| 30 Jun 21 | 0 | -231 | 29 | 204 |
| 31 Mar 21 | 0 | -219 | 24 | 197 |
| 31 Dec 20 | 0 | -202 | 22 | 185 |
| 30 Sep 20 | 0 | -171 | 21 | 156 |
| 30 Jun 20 | 0 | -134 | 20 | 122 |
| 31 Mar 20 | 0 | -105 | 22 | 93 |
| 31 Dec 19 | 0 | -84 | 23 | 72 |
| 30 Sep 19 | 0 | -68 | 23 | 56 |
| 30 Jun 19 | 0 | -55 | 24 | 43 |
| 31 Mar 19 | 0 | -42 | 19 | 33 |
| 31 Dec 18 | 0 | -33 | 15 | 25 |
| 30 Sep 18 | 0 | -30 | 12 | 23 |
| 30 Jun 18 | 0 | -30 | 9 | 24 |
| 31 Mar 18 | 0 | -32 | 8 | 25 |
| 31 Dec 17 | 0 | -31 | 8 | 24 |
| 30 Sep 17 | 0 | -30 | 7 | 23 |
| 30 Jun 17 | 0 | -36 | 9 | 25 |
| 31 Mar 17 | 0 | -31 | 8 | 20 |
| 31 Dec 16 | 0 | -26 | 7 | 16 |
| 30 Sep 16 | 0 | -21 | 5 | 11 |
| 30 Jun 16 | 0 | -8 | 1 | 4 |
| 31 Mar 16 | 0 | -7 | 1 | 3 |
質の高い収益: MDGLは現在利益が出ていません。
利益率の向上: MDGLは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: MDGLは利益が出ておらず、過去 5 年間で損失は年間12%の割合で増加しています。
成長の加速: MDGLの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: MDGLは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 50.1% ) と比較することは困難です。
株主資本利益率
高いROE: MDGLは現在利益が出ていないため、自己資本利益率 ( -47.83% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/30 10:24 |
| 終値 | 2026/04/29 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Madrigal Pharmaceuticals, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28
| アナリスト | 機関 |
|---|---|
| Eliana Merle | Barclays |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |